GlassScriptPhysician profile
Tenecia Allen
NPI 1841478856
$6,818.49
in general payments reported to CMS, 2019-2025
34 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $567 · 2021: $742 · 2022: $1,047 · 2023: $1,279 · 2024: $1,201 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,415.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $796.70 | 2019-2025 | Wainua |
| Amgen INC. | $550.01 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $452.15 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $413.94 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.17 | 2020-2025 | Jardiance |
| Pfizer INC. | $295.09 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.89 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $233.38 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $218.26 | 2019-2022 | |
| Abbott Laboratories | $196.29 | 2021-2025 | Xience Skypoint, Cardiomems |
| Novo Nordisk INC | $163.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Shockwave Medical, INC | $150.00 | 2025 | |
| Cvrx, INC. | $138.85 | 2022-2023 | Barostim Neo System |
| Boston Scientific Corporation | $122.19 | 2019-2024 | Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $119.69 | 2022-2024 | Ffrct |
| Esperion Therapeutics, INC. | $119.12 | 2021-2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $108.62 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.46 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $94.77 | 2019-2023 | |
| Daiichi Sankyo INC. | $69.33 | 2023-2024 | Injectafer |
| Bridgebio Pharma, INC. | $62.12 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $47.63 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $36.24 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.12 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $31.97 | 2024 | Arcalyst |
| W. L. Gore & Associates, INC. | $28.89 | 2021 | |
| Inspire Medical Systems, INC. | $28.76 | 2025 | Inspire |
| Lantheus Medical Imaging, INC. | $22.62 | 2019 | |
| Medtronic Vascular, INC. | $21.29 | 2020 | |
| Gilead Sciences, INC. | $15.79 | 2019 | |
| Scpharmaceuticals INC. | $15.61 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.48 | 2023 | Edarbi |
| Kiniksa Pharmaceuticals, LTD. | $14.75 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tenecia Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.